|
Gene: ANKRD37 |
Gene summary for ANKRD37 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ANKRD37 | Gene ID | 353322 |
Gene name | ankyrin repeat domain 37 | |
Gene Alias | Lrp2bp | |
Cytomap | 4q35.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q7Z713 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
353322 | ANKRD37 | P61T-E | Human | Esophagus | ESCC | 7.06e-21 | 9.58e-01 | 0.099 |
353322 | ANKRD37 | P62T-E | Human | Esophagus | ESCC | 3.04e-85 | 2.69e+00 | 0.1302 |
353322 | ANKRD37 | P65T-E | Human | Esophagus | ESCC | 1.24e-37 | 1.15e+00 | 0.0978 |
353322 | ANKRD37 | P74T-E | Human | Esophagus | ESCC | 5.61e-37 | 1.72e+00 | 0.1479 |
353322 | ANKRD37 | P75T-E | Human | Esophagus | ESCC | 8.00e-37 | 1.66e+00 | 0.1125 |
353322 | ANKRD37 | P76T-E | Human | Esophagus | ESCC | 9.03e-13 | 7.56e-01 | 0.1207 |
353322 | ANKRD37 | P79T-E | Human | Esophagus | ESCC | 3.60e-27 | 1.04e+00 | 0.1154 |
353322 | ANKRD37 | P80T-E | Human | Esophagus | ESCC | 2.50e-47 | 2.58e+00 | 0.155 |
353322 | ANKRD37 | P82T-E | Human | Esophagus | ESCC | 8.19e-08 | 1.47e+00 | 0.1072 |
353322 | ANKRD37 | P83T-E | Human | Esophagus | ESCC | 2.47e-20 | 8.91e-01 | 0.1738 |
353322 | ANKRD37 | P84T-E | Human | Esophagus | ESCC | 2.88e-10 | 9.81e-01 | 0.0933 |
353322 | ANKRD37 | P89T-E | Human | Esophagus | ESCC | 3.39e-09 | 1.74e+00 | 0.1752 |
353322 | ANKRD37 | P91T-E | Human | Esophagus | ESCC | 1.30e-07 | 1.83e+00 | 0.1828 |
353322 | ANKRD37 | P104T-E | Human | Esophagus | ESCC | 3.49e-05 | 6.78e-01 | 0.0931 |
353322 | ANKRD37 | P107T-E | Human | Esophagus | ESCC | 1.78e-23 | 1.10e+00 | 0.171 |
353322 | ANKRD37 | P127T-E | Human | Esophagus | ESCC | 3.34e-05 | 2.87e-01 | 0.0826 |
353322 | ANKRD37 | P128T-E | Human | Esophagus | ESCC | 4.37e-18 | 1.28e+00 | 0.1241 |
353322 | ANKRD37 | P130T-E | Human | Esophagus | ESCC | 2.66e-61 | 2.93e+00 | 0.1676 |
353322 | ANKRD37 | HCC1_Meng | Human | Liver | HCC | 1.82e-10 | 1.74e-02 | 0.0246 |
353322 | ANKRD37 | HCC2_Meng | Human | Liver | HCC | 2.10e-06 | 6.83e-02 | 0.0107 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANKRD37 | SNV | Missense_Mutation | c.25N>A | p.Glu9Lys | p.E9K | Q7Z713 | protein_coding | tolerated(0.08) | possibly_damaging(0.812) | TCGA-D8-A1XB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ANKRD37 | deletion | Frame_Shift_Del | novel | c.216delN | p.Val74LeufsTer7 | p.V74Lfs*7 | Q7Z713 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
ANKRD37 | SNV | Missense_Mutation | c.304N>A | p.Asp102Asn | p.D102N | Q7Z713 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-BI-A20A-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ANKRD37 | SNV | Missense_Mutation | rs761152223 | c.301G>A | p.Glu101Lys | p.E101K | Q7Z713 | protein_coding | deleterious(0.05) | probably_damaging(0.999) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
ANKRD37 | SNV | Missense_Mutation | c.182A>G | p.Asp61Gly | p.D61G | Q7Z713 | protein_coding | deleterious(0) | possibly_damaging(0.695) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ANKRD37 | SNV | Missense_Mutation | rs772390105 | c.364A>G | p.Met122Val | p.M122V | Q7Z713 | protein_coding | tolerated(0.31) | benign(0.006) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ANKRD37 | SNV | Missense_Mutation | c.238C>A | p.Leu80Ile | p.L80I | Q7Z713 | protein_coding | tolerated(0.58) | probably_damaging(0.945) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ANKRD37 | SNV | Missense_Mutation | c.467N>T | p.Arg156Met | p.R156M | Q7Z713 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ANKRD37 | SNV | Missense_Mutation | novel | c.346C>A | p.Leu116Ile | p.L116I | Q7Z713 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANKRD37 | SNV | Missense_Mutation | novel | c.346C>T | p.Leu116Phe | p.L116F | Q7Z713 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |